Back to Search
Start Over
Genetic Basis and Therapies for Vascular Anomalies.
- Source :
-
Circulation research [Circ Res] 2021 Jun 25; Vol. 129 (1), pp. 155-173. Date of Electronic Publication: 2021 Jun 24. - Publication Year :
- 2021
-
Abstract
- Vascular and lymphatic malformations represent a challenge for clinicians. The identification of inherited and somatic mutations in important signaling pathways, including the PI3K (phosphoinositide 3-kinase)/AKT (protein kinase B)/mTOR (mammalian target of rapamycin), RAS (rat sarcoma)/RAF (rapidly accelerated fibrosarcoma)/MEK (mitogen-activated protein kinase kinase)/ERK (extracellular signal-regulated kinases), HGF (hepatocyte growth factor)/c-Met (hepatocyte growth factor receptor), and VEGF (vascular endothelial growth factor) A/VEGFR (vascular endothelial growth factor receptor) 2 cascades has led to the evaluation of tailored strategies with preexisting cancer drugs that interfere with these signaling pathways. The era of theranostics has started for the treatment of vascular anomalies. Registration: URL: https://www.clinicaltrialsregister.eu; Unique identifier: 2015-001703-32.
- Subjects :
- Angiogenesis Inhibitors adverse effects
Animals
Blood Vessels metabolism
Genetic Predisposition to Disease
Humans
Molecular Targeted Therapy
Phenotype
Protein Kinase Inhibitors adverse effects
Signal Transduction
Vascular Malformations metabolism
Vascular Malformations pathology
Angiogenesis Inhibitors therapeutic use
Blood Vessels abnormalities
Blood Vessels drug effects
Mutation
Neovascularization, Physiologic drug effects
Protein Kinase Inhibitors therapeutic use
Vascular Malformations drug therapy
Vascular Malformations genetics
Subjects
Details
- Language :
- English
- ISSN :
- 1524-4571
- Volume :
- 129
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Circulation research
- Publication Type :
- Academic Journal
- Accession number :
- 34166070
- Full Text :
- https://doi.org/10.1161/CIRCRESAHA.121.318145